Nuvation Bio (NUVB) Research Hub

Nuvation Bio (NUVB) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.51 USD (-1.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -15.43, market cap 2.12B. This hub links to the full technical, earnings and options research available for NUVB.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNYSE, US
Last close4.51 USD (-1.31%)
52-week range4.35 USD – 7.58 USD
Trend regimeRange
14-day RSI38.4 (Bearish)
Trailing P/E-15.43
Market cap2.12B
Dividend yield0.00%
Next earnings2026-08-06

Available research for NUVB

Earnings

NUVB earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -15.43. Updated 2026-07-23.

Options: Covered Call

Covered Call on NUVB: how it works, illustrative setup around the real 4.51 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on NUVB: how it works, illustrative setup around the real 4.51 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on NUVB: how it works, illustrative setup around the real 4.51 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

NUVB technical analysis: range, last 4.51 USD, RSI 38.4, 52w range 4.35 USD–7.58 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is NUVB in?

Nuvation Bio (NUVB) is classified under Healthcare (Biotechnology), listed on NYSE, US.

Is NUVB in an uptrend or downtrend?

As of 2026-10-26, NUVB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is NUVB's trailing P/E ratio?

NUVB's trailing P/E is -15.43, with a market cap of 2.12B. See the earnings research page for full valuation detail.

When does NUVB next report earnings?

NUVB is next scheduled to report earnings on 2026-08-06.